Conjugated Via A Specifically-identified Linking Group, Coupling Agent, Or Conjugation Agent Patents (Class 530/391.9)
-
Publication number: 20130280125Abstract: Disclosed is an antibacterial composition comprising titanium oxide particles immobilized with an antibody having affinity and cognitive power to a microorganism of interest, and a method for sterilizing the microorganism by using the same. In particular, the present invention relates to a method for preparing functional titanium oxide particles capable of recognizing a microorganism or a virus of interest, and a method for selectively and efficiently sterilizing the same by using the functional titanium oxide particles, and not for randomly sterilizing microorganisms or viruses by using conventional titanium oxide particles having no recognition power to a microorganism or a virus of interest.Type: ApplicationFiled: November 8, 2012Publication date: October 24, 2013Inventors: Byoung Chan KIM, Jon Soo JURNG, Min Young SONG
-
Publication number: 20130280279Abstract: The present invention relates to a pharmaceutical composition of complex of a monospecific antibody that binds to digoxigenin, and a digoxigenin-conjugated peptide, to the isolated or recovered complex as well as to a method of producing such complex or composition. Furthermore the use of such a pharmaceutical composition as a medicament is described.Type: ApplicationFiled: June 27, 2013Publication date: October 24, 2013Inventors: Ulrich Brinkmann, Sebastian Dziadek, Eike Hoffmann
-
Publication number: 20130281679Abstract: The present invention relates to a conjugate of acetylated biocompatible polysaccharide and phthalocyanine-based compound for photodynamic diagnosis or therapy and to a method for preparing the same, and more particularly, to a conjugate for photodynamic diagnosis or therapy and to a method for preparing the same, in which biocompatible polysaccharide is acetylated and a phthalocyanine-based compound is bound to the acetylated polysaccharide. The conjugate for photodynamic diagnosis or therapy according to the present invention is characterized in that the polysaccharide is acetylated to improve solubility in a solvent and thus enable various chemical modifications, and the conjugate may specifically target tumor cells, has superior cancer cell selecting and accumulating capacity, and has excellent effects of killing cancer cells when near infrared ray is irradiated.Type: ApplicationFiled: December 21, 2011Publication date: October 24, 2013Applicant: Panaxem Co., Ltd.Inventors: Kun Na, Fang Yuan Li, Byoung Chan Bae
-
Publication number: 20130280280Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: ApplicationFiled: March 12, 2013Publication date: October 24, 2013Applicant: GLAXOSMITHKLINEInventor: GLAXOSMITHKLINE
-
Publication number: 20130280282Abstract: Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent that are effective in treatment of various cancers.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Applicants: Daiichi Sankyo Co., Ltd., Seattle Genetics, Inc.Inventors: Toshiaki Ohtsuka, Kimihisa Ichikawa, Ayumi Yada
-
Patent number: 8563692Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).Type: GrantFiled: January 5, 2011Date of Patent: October 22, 2013Assignee: The Regents of the University of CaliforniaInventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
-
Publication number: 20130266579Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.Type: ApplicationFiled: March 8, 2013Publication date: October 10, 2013Inventors: Ge Wei, Gregory I. Frost, Lei Huang, H. Michael Shepard, Daniel Edward Vaughn
-
Publication number: 20130266596Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: February 22, 2013Publication date: October 10, 2013Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Publication number: 20130266595Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.Type: ApplicationFiled: October 12, 2012Publication date: October 10, 2013Inventors: John A. Flygare, Janet L. Gunzner-Toste, Thomas Pillow, Philip Wilson Howard, Luke Masterson
-
Publication number: 20130259882Abstract: Anti-tumor conjugates, which consists of foliate or analogues thereof, linkers, an antibodies such as immunoglobulin G. The linker comprises glutathione, cysteamine or cysteine residue, and further comprises N-hydroxysuccinimide. The Conjugates target folate-receptor-positive tumor cells. Also provided are preparation methods and anti-tumor and anti-autoimmune disease uses of the conjugates.Type: ApplicationFiled: May 14, 2011Publication date: October 3, 2013Inventor: Ying Liu
-
Publication number: 20130259881Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.Type: ApplicationFiled: May 13, 2013Publication date: October 3, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
-
Publication number: 20130259880Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by a linker comprising a urea moiety, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: September 29, 2011Publication date: October 3, 2013Applicant: HEIDELBERG PHARMA GMBHInventors: Jan Anderl, Werner Simon, Christoph Mueller
-
Patent number: 8545850Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.Type: GrantFiled: November 5, 2010Date of Patent: October 1, 2013Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8541178Abstract: Methods to detect, characterize, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by immunoaffinity bead separation, chromatography, and mass spectrometry are disclosed; Ab-(L-D)p??I wherein Ab is an antibody; D is a drug moiety; L is a linker covalently attached to Ab, and covalently attached to D; and p is 1, 2, 3, 4, 5, 6, 7, or 8.Type: GrantFiled: May 12, 2009Date of Patent: September 24, 2013Assignee: Genentech, Inc.Inventors: Surinder Kaur, Ola Saad, Keyang Xu
-
Publication number: 20130224229Abstract: The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H3CO A represents —CH2—CH2— or —CH?CH—; L represents —C(O)—(NH)n1—R—(NH)n2—C(O)—; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms in the chain is 24; and wherein the carbon atoms of the chain can be replaced by at least one heteroatom, wherein the heteroatoms are independently —O— or —NH2—, with the proviso that each heteroatom is separated from each other heteroatom by at least two carbon atoms; n1 and n2 independently represent 0 or 1; and Y represents an antibody that binds specifically to a target antigen of a tumor cell. The invention further relates to methods of method of inhibiting the growth of tumors in a human by administering an effective amount of the curcumin derivative, and to methods of producing the curcumin derivative.Type: ApplicationFiled: December 1, 2010Publication date: August 29, 2013Applicant: Research Foundation of the City University of New YorkInventors: Probal Banerjee, Raja Krishnaswami
-
Publication number: 20130224228Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.Type: ApplicationFiled: December 4, 2012Publication date: August 29, 2013Applicant: Igenica, Inc.Inventor: Igenica, Inc.
-
Publication number: 20130211053Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.Type: ApplicationFiled: January 31, 2013Publication date: August 15, 2013Applicant: WYETH LLCInventors: George Anello CHIARELLO, Ayman SAHLI
-
Publication number: 20130189287Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs.Type: ApplicationFiled: December 21, 2012Publication date: July 25, 2013Applicants: Innate PharmaInventors: Innate Pharma, Paul Scherrer Institut
-
Patent number: 8470980Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.Type: GrantFiled: September 9, 2010Date of Patent: June 25, 2013Assignee: Centrose, LLCInventors: James R. Prudent, Jon S. Thorson, Jill Hutchinson Bollettieri
-
Patent number: 8461311Abstract: Disclosed are TNF-related apoptosis-inducing ligand (TRAIL) trimers (TR3) and nucleic acids encoding covalently linked TRAIL trimers. A TRAIL trimer can have greater stability compared to native TRAIL, and can retain the native killing ability of TRAIL. Target specificity of a TR3 can be shown by blocking its activity with soluble death receptor 5 (DR5-Fc). Also disclosed are modified TRAIL trimers and nucleic. acids encoding them. These modifications include additional functional domains, such as antibody fragments (scFvs). A TR3 comprising an additional functional domain can allow for cell-specific delivery of the TR3. The inventors disclose TR3-decorated RBCs that target cell killing in a model of pancreatic cancer.Type: GrantFiled: June 8, 2011Date of Patent: June 11, 2013Assignee: Washington UniversityInventors: William G. Hawkins, Dirk Spitzer, Richard S. Hotchkiss
-
Patent number: 8455622Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.Type: GrantFiled: December 1, 2007Date of Patent: June 4, 2013Assignee: Seattle Genetics, Inc.Inventors: Charlotte McDonagh, Paul Carter, Django Sussman
-
Patent number: 8449888Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.Type: GrantFiled: September 16, 2011Date of Patent: May 28, 2013Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
-
Publication number: 20130129753Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: ApplicationFiled: November 7, 2012Publication date: May 23, 2013Applicant: PFIZER INC.Inventor: PFIZER INC.
-
Publication number: 20130122020Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: ApplicationFiled: November 7, 2012Publication date: May 16, 2013Applicant: RINAT NEUROSCIENCE CORP.Inventor: Rinat Neuroscience Corp.
-
Publication number: 20130122024Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: April 20, 2012Publication date: May 16, 2013Applicant: Bayer Intellectual Property GmbHInventors: Hans-Georg LERCHEN, Beatrix STELTE-LUDWIG, Sven GOLFIER, Charlotte Christine KOPITZ, Rudolf BEIER, Sherif EL SHEIKH, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Joachim SCHUHMACHER, Sandra BRUDER, Simone GREVEN, Lars LINDEN, Jörg WILLUDA, Christoph MAHLERT, Heike PETRUL, Hannah JÖRIßEN, Sandra Borkowski
-
Patent number: 8436147Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.Type: GrantFiled: October 26, 2007Date of Patent: May 7, 2013Assignee: Genentech, Inc.Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
-
Publication number: 20130108620Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.Type: ApplicationFiled: November 28, 2011Publication date: May 2, 2013Applicants: GENENTECH, INC., IMMUNOGEN INC.Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Gail Colbern Schwall
-
Publication number: 20130108653Abstract: The present invention relates to a new class of virus fusion inhibitors or virus entry inhibitors. More specifically the present invention relates to bivalent molecules that are pre-fusion inhibitors of viruses that makes use of the type (1) fusion mechanism belonging to the groups consisting of Othomyxoviridae, Paramyxoviridae, Retroviridae, Filoviridae and Coronaviridae, in particular HIV. The bivalent molecules of the present invention are molecules that comprise a first part capable of mimicking the function of a mammalian cell receptor, and a second part capable of binding to a virus, preferably HIV, resulting in the neutralization of the virus which is thus rendered harmless. Further, the present invention relates to compositions comprising the pre-fusion inhibitors, as well as to methods for obtaining the pre-fusion inhibitors and the use of the pre-fusion inhibitors.Type: ApplicationFiled: December 22, 2010Publication date: May 2, 2013Inventors: Shervin Bahrami, Martin Tolstrup, Mogens Duch Ryttergmrd, Finn Skou Pedersen, Lars Jørgen Ostergaard
-
Publication number: 20130101608Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.Type: ApplicationFiled: June 15, 2011Publication date: April 25, 2013Applicant: GENMAB A/SInventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
-
Publication number: 20130095123Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: October 20, 2012Publication date: April 18, 2013Applicants: SEATTLE GENETICS, INC., BAYER INTELLECTUAL PROPERTY GMBHInventors: Bayer Pharma AG, Bayer Intellectual Property GmbH, Seattle Genetics, Inc.
-
Publication number: 20130090458Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: ApplicationFiled: December 5, 2012Publication date: April 11, 2013Applicant: IMMUNOMEDICS, INC.Inventor: Immunomedics, Inc.
-
Patent number: 8409577Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: GrantFiled: June 12, 2007Date of Patent: April 2, 2013Assignee: Emergent Product Development Seattle, LLCInventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
-
Publication number: 20130078243Abstract: This invention relates to a therapeutic molecule capable of suppressing an immune response against an organ or tissue transplantation in a patient. In particular, the invention relates to a conjugate comprising a first portion connected to a second portion, wherein the first portion binds to an MHC Class I molecule and the second portion has HLA-G activity. This conjugate may be used as a medicament to modulate immune responses and induce immunological tolerance specific to allogenic MHC complexes.Type: ApplicationFiled: November 11, 2010Publication date: March 28, 2013Applicant: King's College Hospital NHS Foundation TrustInventor: Mohammad Ibrahim
-
Publication number: 20130078237Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: ApplicationFiled: September 20, 2012Publication date: March 28, 2013Inventors: John M. DELANEY, William Christian FANSLOW, III, Chadwick Terence KING
-
Publication number: 20130072659Abstract: The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.Type: ApplicationFiled: November 7, 2012Publication date: March 21, 2013Applicant: IMMUNOMEDICS, INC.Inventor: IMMUNOMEDICS, INC.
-
Publication number: 20130066055Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: April 20, 2012Publication date: March 14, 2013Applicant: Bayer Intellectual Property GmbHInventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte Christine Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörissen, Sandra Borkowski
-
Publication number: 20130040361Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.Type: ApplicationFiled: August 9, 2012Publication date: February 14, 2013Inventors: Jascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
-
Publication number: 20130030160Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.Type: ApplicationFiled: June 20, 2012Publication date: January 31, 2013Applicant: Ambrx, Inc.Inventors: Zhenwei MIAO, Junjie Liu, Thea Norman, Russell Driver
-
Publication number: 20130028919Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.Type: ApplicationFiled: April 15, 2011Publication date: January 31, 2013Applicants: SPIROGEN DEVELOPMENTS SÀRL, SEATTLE GENETICS, INC.Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
-
Publication number: 20130028917Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.Type: ApplicationFiled: April 15, 2011Publication date: January 31, 2013Applicant: SPIROGEN DEVELOPMENTS SÀRLInventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien, John A. Flygare, Janet L. Gunzner, Paul Polakis, Andrew Polson, Helga E. Raab, Susan D. Spencer
-
Publication number: 20130028918Abstract: The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: ApplicationFiled: April 4, 2011Publication date: January 31, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Patent number: 8362213Abstract: Anti-FcRH5 antibodies and immunoconjugates thereof are provided. Methods of using anti-FcRH5 antibodies and immunoconjugates thereof are provided.Type: GrantFiled: March 31, 2010Date of Patent: January 29, 2013Assignee: Genentech, Inc.Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
-
Publication number: 20130022626Abstract: The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof.Type: ApplicationFiled: April 4, 2011Publication date: January 24, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Chang Hwan Kim, Sung Kap Hong, Byung Sun Lee, Soo Young Kwak, Mi Ji Lee, In Young Choi, Se Chang Kwon
-
Publication number: 20130011419Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: July 5, 2012Publication date: January 10, 2013Applicant: ImmunoGen, INC.Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20130012435Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: June 26, 2012Publication date: January 10, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
-
Publication number: 20130004432Abstract: Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells.Type: ApplicationFiled: December 8, 2010Publication date: January 3, 2013Inventors: Michel Pierres, Eric Vivier, Myriam Baratin
-
Publication number: 20120321624Abstract: Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neuromuscular junctions and treating diseases and conditions affecting the neuromuscular junction include administering a composition including a neuromuscular junction targeting peptide coupled to a therapeutic agent.Type: ApplicationFiled: June 19, 2012Publication date: December 20, 2012Inventors: Henry Kaminski, Linda Kusner, Namita Satija
-
Patent number: 8329191Abstract: The present invention relates to three-branched PEG-G-CSF conjugate of general formula (1) in which the bonding ratio of three-branched polyethylene glycol (PEG) and G-CSF is 1:1 (mol/mol), wherein PEG has an average molecular weight of from 200 to 45,000 daltons; a pharmaceutical composition comprising the same, and a preparing method thereof.Type: GrantFiled: November 22, 2006Date of Patent: December 11, 2012Assignee: Dong-A-Pharm. Co., Ltd.Inventors: Yeong-Woo Jo, Won-Young Yoo, Hyun-Kyu Jeon, Yun-Kyu Choi, Hye-In Jang, Byong-Moon Kim, Sung-Hee Lee, Soo-Hyung Kang, Moo-Hi Yoo
-
Publication number: 20120276098Abstract: The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.Type: ApplicationFiled: September 23, 2010Publication date: November 1, 2012Inventors: Bruce Hamilton, Christopher Herring, Mark Andrew Paulik
-
Patent number: RE43899Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.Type: GrantFiled: January 12, 2012Date of Patent: January 1, 2013Assignee: Immunogen Inc.Inventors: Walter A. Blättler, Ravi V. J. Chari